Absolute quantification of viral proteins from pseudotyped VSV-GP using UPLC-MRM
The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral protein...
Saved in:
| Published in | Microbiology spectrum Vol. 12; no. 8; p. e0365123 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
06.08.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. |
|---|---|
| AbstractList | The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC).The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC).The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP.IMPORTANCEThe development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC).IMPORTANCEThe development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC). The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. ABSTRACT The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC).IMPORTANCEThe development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new biotherapeutic emerging in the oncolytic viral therapy platform. Novel analytical assays that can accurately and precisely quantify the viral proteins are a necessity for the successful development of viral vector as a biotherapeutic. We developed an ultra-high performance liquid chromatography multiple reaction monitoring-based assay to quantify the absolute concentrations of the different structural proteins of VSV-GP. The complete processing of GP complex (GPC) is a prerequisite for the infectivity of the virus. The assay extends the potential for quantifying full-length GPC, which provides an understanding of the processing of GPC (along with the quantification of GP1 and GP2 separately). We used this assay in tracking GPC processing in HEK-293-F production cell lines infected with VSV-GP. The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of the virus during production and development. Accurate monitoring and absolute quantification of viral proteins are crucial for OV product characterization and can facilitate the understanding of infection, immunogenicity, and development stages of viral replication. Targeted mass spectrometry methods like multiple reaction monitoring (MRM) offer a robust way to directly detect and quantify specific targeted proteins represented by surrogate peptides. We have leveraged the power of MRM by combining ultra-high performance liquid chromatography (UPLC) with a Sciex 6500 triple-stage quadrupole mass spectrometer to develop an assay that accurately and absolutely quantifies the structural proteins of a pseudotyped vesicular stomatitis virus (VSV) intended for use as a new biotherapeutic (designated hereafter as VSV-GP to differentiate it from native VSV). The new UPLC-MRM method provides absolute quantification with the use of heavy-labeled reference standard surrogate peptides. When added in known exact amounts to standards and samples, the reference standards normalize and account for any small perturbations during sample preparation and/or instrument performance, resulting in accurate and precise quantification. Because of the multiplexed nature of MRM, all targeted proteins are quantified at the same time. The optimized assay has been enhanced to quantify the ratios of the processed GP1 and GP2 proteins while simultaneously measuring any remaining or unprocessed form of the envelope protein GP complex (GPC; full-length GPC). |
| Author | Jiang, Di Dambra, Richard Papov, Vladimir V. Chiramel, Abhilash I. Schätzlein, Sophia A. Vigil, Adam Njiyang, Shu Ashour, Joseph Basu, Rajeswari |
| Author_xml | – sequence: 1 givenname: Rajeswari orcidid: 0009-0000-7957-0601 surname: Basu fullname: Basu, Rajeswari organization: Materials and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA – sequence: 2 givenname: Richard surname: Dambra fullname: Dambra, Richard organization: Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA – sequence: 3 givenname: Di surname: Jiang fullname: Jiang, Di organization: Materials and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA – sequence: 4 givenname: Sophia A. surname: Schätzlein fullname: Schätzlein, Sophia A. organization: Therapeutic Virus Development Group, Virus Therapeutic Center, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany – sequence: 5 givenname: Shu surname: Njiyang fullname: Njiyang, Shu organization: Therapeutic Virus Development Group, Virus Therapeutic Center, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany – sequence: 6 givenname: Joseph surname: Ashour fullname: Ashour, Joseph organization: Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA – sequence: 7 givenname: Abhilash I. surname: Chiramel fullname: Chiramel, Abhilash I. organization: Therapeutic Virus Development Group, Virus Therapeutic Center, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany – sequence: 8 givenname: Adam surname: Vigil fullname: Vigil, Adam organization: Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA – sequence: 9 givenname: Vladimir V. orcidid: 0000-0003-2494-7824 surname: Papov fullname: Papov, Vladimir V. organization: Materials and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38916347$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUtP3DAURq2KqjzKD-imyrKbDH4ktmdVoVFLkQZ11Ba2lh_XU4-SONgOEv--gQEEi65s-R4f3Xu_Y3QwxAEQ-kTwghAqz_IItqSpX2DGW1JT9g4dUcLbGjdLcfDqfohOc95hjAnBLW3pB3TI5JJw1ogjtDk3OXZTgep20kMJPlhdQhyq6Ku7kHRXjSkWCEOufIp9NWaYXCz3I7jq5vdNfbGpphyGbXW9Wa_qq19XH9F7r7sMp0_nCbr-_u3P6ke9_nlxuTpf17ppRamt47DUFJbSGqG1FMZpAs5h6YkBkNxrYYTHTht4qDngkjcUmJGea-HYCbrce13UOzWm0Ot0r6IO6vEhpq3SqQTbgXItbbT0mBvBGuq8XEpHpLaWtY4Z18yur3vXOJkenIWhzJO_kb6tDOGv2sY7RQjDVFAxG748GVK8nSAX1Ydsoev0AHHKimFB5wC4kDO62KM691Tt4pSGeU-KYPUQq3qOVT3GqiibP3x-3d1LW88hzgDZAzbFnBP4F-T_0n_xo7Tx |
| Cites_doi | 10.1016/0042-6822(83)90087-9 10.1038/s41434-018-0034-7 10.1186/1743-422X-5-161 10.1385/1597452556 10.1128/JVI.54.2.598-607.1985 10.1038/s41541-021-00317-4 10.1186/1471-2105-13-S16-S9 10.1021/ac50048a002 10.3389/fbioe.2020.603488 10.1128/JVI.02759-06 10.1128/JVI.01371-15 10.3389/fbioe.2022.992069 10.1016/j.ab.2007.06.043 10.1021/pr800535h 10.1016/j.omtm.2022.12.013 10.1074/mcp.O112.020131 10.1016/j.ab.2008.03.009 10.1371/journal.pone.0131137 10.1038/nmeth.f.371 10.1073/pnas.0832254100 10.1021/acs.jproteome.9b00640 10.1128/JVI.01400-10 10.1128/JVI.73.6.4705-4712.1999 10.1038/nmeth.2015 10.1021/ac50023a781 10.1038/s41467-022-32223-1 10.1042/BSR20211930 10.1007/s10337-016-3121-1 10.1186/1743-422X-6-147 10.1007/978-1-59745-255-7 10.3389/fviro.2023.1108420 10.1074/mcp.M800540-MCP200 10.1074/mcp.M700132-MCP200 10.1128/JVI.02039-09 10.1074/mcp.M110.006593 10.1002/jms.4348 10.1053/j.gastro.2019.04.003 10.1128/JVI.3.4.395-403.1969 10.1021/acs.analchem.1c01613 10.1073/pnas.73.5.1504 10.1080/14760584.2022.2072302 10.1016/j.ymeth.2004.08.018 10.1002/bmc.5287 10.1128/mBio.02063-14 10.1021/pr801122b 10.1016/s0042-6822(03)00421-5 10.1016/j.jmb.2023.168096 10.1016/j.celrep.2019.12.024 10.1038/msb.2008.61 10.1038/nsmb.3210 10.1128/JVI.67.12.7246-7253.1993 10.1073/pnas.221447598 10.1128/JVI.3.6.611-618.1969 10.1016/j.cell.2015.06.018 10.1128/JVI.03276-13 10.1073/pnas.0903228106 10.1074/mcp.T500029-MCP200 10.1158/0008-5472.CAN-13-3306 10.3390/v12020223 10.1074/mcp.M500230-MCP200 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Basu et al. Copyright © 2024 Basu et al. 2024 Basu et al. |
| Copyright_xml | – notice: Copyright © 2024 Basu et al. – notice: Copyright © 2024 Basu et al. 2024 Basu et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.03651-23 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | Miranda, J. J. |
| Editor_xml | – sequence: 1 givenname: J. J. surname: Miranda fullname: Miranda, J. J. |
| ExternalDocumentID | oai_doaj_org_article_d524a8f06b7342df898d18acc35d3bd4 PMC11302727 spectrum03651-23 38916347 10_1128_spectrum_03651_23 |
| Genre | Journal Article |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV AGVNZ ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF NPM UCJ 7X8 5PM |
| ID | FETCH-LOGICAL-a457t-cd6e9a2e98cb7aa87bda1edd08f1bee86fa7b7f0dabe7bdade68642e3b8f6a7d3 |
| IEDL.DBID | AAUOK |
| ISSN | 2165-0497 |
| IngestDate | Wed Aug 27 01:20:57 EDT 2025 Thu Aug 21 18:31:53 EDT 2025 Fri Jul 11 04:53:41 EDT 2025 Tue Aug 06 18:20:14 EDT 2024 Mon Jul 21 06:02:21 EDT 2025 Tue Jul 01 00:42:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | GPC tracking oncolytic virus absolute quantification |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a457t-cd6e9a2e98cb7aa87bda1edd08f1bee86fa7b7f0dabe7bdade68642e3b8f6a7d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Denali Therapeutics Inc., Development Sciences, South San Francisco, California, USA All authors were employed by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) at the time of the experiments. Present address: Regeneron Pharmaceuticals, Tarrytown, New York, USA The authors declare no conflict of interest. |
| ORCID | 0009-0000-7957-0601 0000-0003-2494-7824 |
| OpenAccessLink | https://journals.asm.org/doi/10.1128/spectrum.03651-23 |
| PMID | 38916347 |
| PQID | 3072001678 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d524a8f06b7342df898d18acc35d3bd4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11302727 proquest_miscellaneous_3072001678 asm2_journals_10_1128_spectrum_03651_23 pubmed_primary_38916347 crossref_primary_10_1128_spectrum_03651_23 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-06 |
| PublicationDateYYYYMMDD | 2024-08-06 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Spectrum |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2024 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_50_2 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 Shabir GA (e_1_3_3_46_2) 2004 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_58_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_61_2 e_1_3_3_5_2 e_1_3_3_7_2 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) (e_1_3_3_44_2) 2022 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_63_2 e_1_3_3_51_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_59_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_57_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_62_2 e_1_3_3_60_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_26_2 (e_1_3_3_45_2) 1994 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_64_2 Janecki, DJ, Bemis, KG, Tegeler, TJ, Sanghani, PC, Zhai, L, Hurley, TD, Bosron, WF, Wang, M (B10) 2007; 369 Branco, LM, Garry, RF (B50) 2009; 6 Liang, B, Li, Z, Jenni, S, Rahmeh, AA, Morin, BM, Grant, T, Grigorieff, N, Harrison, SC, Whelan, SPJ (B56) 2015; 162 Muik, A, Stubbert, LJ, Jahedi, RZ, Geiβ, Y, Kimpel, J, Dold, C, Tober, R, Volk, A, Klein, S, Dietrich, U, Yadollahi, B, Falls, T, Miletic, H, Stojdl, D, Bell, JC, von Laer, D (B22) 2014; 74 Yost, RA, Enke, CG (B8) 1979; 51 Zhang, H, Liu, Q, Zimmerman, LJ, Ham, A-J, Slebos, RJC, Rahman, J, Kikuchi, T, Massion, PP, Carbone, DP, Billheimer, D, Liebler, DC (B46) 2011; 10 Picotti, P, Aebersold, R (B6) 2012; 9 Lothert, K, Eilts, F, Wolff, MW (B3) 2022; 21 Mani, DR, Abbatiello, SE, Carr, SA (B63) 2012; 13 Saveliev, S, Bratz, M, Zubarev, R, Szapacs, M, Budamgunta, H, Urh, M (B62) 2013; 10 Rosen, CA, Cohen, PS, Ennis, HL (B55) 1983; 130 Dambra, R, Matter, A, Graca, K, Akhand, SS, Mehta, S, Bell-Cohn, A, Swenson, JM, Abid, S, Xin, D, Lewis, C, Coyle, L, Wang, M, Bunosso, K, Maugiri, M, Ruiz, R, Cirillo, CM, Fogal, B, Grimaldi, C, Vigil, A, Wood, C, Ashour, J (B58) 2023; 28 Ulintz, PJ, Yocum, AK, Bodenmiller, B, Aebersold, R, Andrews, PC, Nesvizhskii, AI (B12) 2009; 8 Wagner, RR, Schnaitman, TC, Snyder, RM, Schnaitman, CA (B29) 1969; 3 Illick, MM, Branco, LM, Fair, JN, Illick, KA, Matschiner, A, Schoepp, R, Garry, RF, Guttieri, MC (B52) 2008; 5 Kuzyk, MA, Smith, D, Yang, J, Cross, TJ, Jackson, AM, Hardie, DB, Anderson, NL, Borchers, CH (B13) 2009; 8 Kondrat, RW, Cooks, RG (B7) 1978; 50 Pennington, HN, Lee, J (B34) 2022; 42 Mayya, V, Rezual, K, Wu, L, Fong, MB, Han, DK (B16) 2006; 5 Jenni, S, Horwitz, JA, Bloyet, L-M, Whelan, SPJ, Harrison, SC (B57) 2022; 13 Thomas, D, Newcomb, WW, Brown, JC, Wall, JS, Hainfeld, JF, Trus, BL, Steven, AC (B40) 1985; 54 Sherwood, CA, Eastham, A, Lee, LW, Risler, J, Mirzaei, H, Falkner, JA, Martin, DB (B9) 2009; 8 Ball, LA, Pringle, CR, Flanagan, B, Perepelitsa, VP, Wertz, GW (B47) 1999; 73 Schlie, K, Maisa, A, Lennartz, F, Ströher, U, Garten, W, Strecker, T (B51) 2010; 84 Soh, TK, Whelan, SPJ (B42) 2015; 89 Lin, Y, Zhou, J, Bi, D, Chen, P, Wang, X, Liang, S (B61) 2008; 377 Salvatore, S, Gerber, SA, Kettenbach, AN, Rush, J, Gygi, SP (B19) 2006 Bederka, LH, Bonhomme, CJ, Ling, EL, Buchmeier, MJ (B31) 2014; 5 Riepler, L, Frommelt, L-S, Wilmschen-Tober, S, Mbuya, W, Held, K, Volland, A, von Laer, D, Geldmacher, C, Kimpel, J (B20) 2023; 435 Adams, KJ, Pratt, B, Bose, N, Dubois, LG, St John-Williams, L, Perrott, KM, Ky, K, Kapahi, P, Sharma, V, MacCoss, MJ, Moseley, MA, Colton, CA, MacLean, BX, Schilling, B, Thompson, JW (B36) 2020; 19 Gerber, SA, Rush, J, Stemman, O, Kirschner, MW, Gygi, SP (B18) 2003; 100 Abraham, G, Banerjee, AK (B24) 1976; 73 Redondo, N, Madan, V, Alvarez, E, Carrasco, L (B54) 2015; 10 Stahl-Zeng, J, Lange, V, Ossola, R, Eckhardt, K, Krek, W, Aebersold, R, Domon, B (B38) 2007; 6 B44 Bosma, B, du Plessis, F, Ehlert, E, Nijmeijer, B, de Haan, M, Petry, H, Lubelski, J (B30) 2018; 25 Gerber, SA, Kettenbach, AN, Rush, J, Gygi, SP (B17) 2007; 359 Liigand, P, Kaupmees, K, Kruve, A (B53) 2019; 54 Wagner, RR, Schnaitman, TA, Snyder, RM (B26) 1969; 3 Tisoncik-Go, J, Voss, KM, Lewis, TB, Muruato, AE, Kuller, L, Finn, EE, Betancourt, D, Wangari, S, Ahrens, J, Iwayama, N, Grant, RF, Murnane, RD, Edlefsen, PT, Fuller, DH, Barber, GN, Gale, M, O’Connor, MA (B21) 2023; 3 Lange, V, Picotti, P, Domon, B, Aebersold, R (B37) 2008; 4 Gao, Y, Fillmore, TL, Munoz, N, Bentley, GJ, Johnson, CW, Kim, J, Meadows, JA, Zucker, JD, Burnet, MC, Lipton, AK, Bilbao, A, Orton, DJ, Kim, Y-M, Moore, RJ, Robinson, EW, Baker, SE, Webb-Robertson, B-JM, Guss, AM, Gladden, JM, Beckham, GT, Magnuson, JK, Burnum-Johnson, KE (B5) 2020; 8 Peterson, AC, Russell, JD, Bailey, DJ, Westphall, MS, Coon, JJ (B14) 2012; 11 Kunz, S, Edelmann, KH, de la Torre, J-C, Gorney, R, Oldstone, MBA (B35) 2003; 314 Tober, R, Banki, Z, Egerer, L, Muik, A, Behmüller, S, Kreppel, F, Greczmiel, U, Oxenius, A, von Laer, D, Kimpel, J (B23) 2014; 88 Matraszek-Zuchowska, I, Wozniak, B, Posyniak, A (B11) 2016; 79 González-Domínguez, I, Puente-Massaguer, E, Cervera, L, Gòdia, F (B2) 2020; 12 Silva, JC, Gorenstein, MV, Li, G-Z, Vissers, JPC, Geromanos, SJ (B60) 2006; 5 (B43) 2022 Jenni, S, Bloyet, L-M, Diaz-Avalos, R, Liang, B, Whelan, SPJ, Grigorieff, N, Harrison, SC (B28) 2020; 30 Barge, A, Gaudin, Y, Coulon, P, Ruigrok, RW (B41) 1993; 67 Sanyal, G, Särnefält, A, Kumar, A (B1) 2021; 6 Green, TJ, Luo, M (B27) 2009; 106 Gautam, S, Xin, D, Garcia, AP, Spiesschaert, B (B59) 2022; 10 Hastie, KM, Igonet, S, Sullivan, BM, Legrand, P, Zandonatti, MA, Robinson, JE, Garry, RF, Rey, FA, Oldstone, MB, Saphire, EO (B33) 2016; 23 Lupberger, J, Croonenborghs, T, Roca Suarez, AA, Van Renne, N, Jühling, F, Oudot, MA, Virzì, A, Bandiera, S, Jamey, C, Meszaros, G (B4) 2019; 157 Zhong, X, Nayak, S, Guo, L, Raidas, S, Zhao, Y, Weiss, R, Andisik, M, Elango, C, Sumner, G, Irvin, SC, Partridge, MA, Yan, H, E, SY, Qiu, H, Mao, Y, Torri, A, Li, N (B48) 2021; 93 Shabir, GA (B45) 2004; 16 Kirkpatrick, DS, Gerber, SA, Gygi, SP (B15) 2005; 35 Lenz, O, ter Meulen, J, Klenk, H-D, Seidah, NG, Garten, W (B49) 2001; 98 Raux, H, Obiang, L, Richard, N, Harper, F, Blondel, D, Gaudin, Y (B25) 2010; 84 Wang, C, Wang, Y, Xie, H, Zhan, C, He, X, Liu, R, Hu, R, Shen, J, Jia, Y (B39) 2022; 36 Saunders, AA, Ting, JPC, Meisner, J, Neuman, BW, Perez, M, de la Torre, JC, Buchmeier, MJ (B32) 2007; 81 |
| References_xml | – ident: e_1_3_3_56_2 doi: 10.1016/0042-6822(83)90087-9 – ident: e_1_3_3_31_2 doi: 10.1038/s41434-018-0034-7 – ident: e_1_3_3_53_2 doi: 10.1186/1743-422X-5-161 – ident: e_1_3_3_20_2 doi: 10.1385/1597452556 – ident: e_1_3_3_41_2 doi: 10.1128/JVI.54.2.598-607.1985 – ident: e_1_3_3_2_2 doi: 10.1038/s41541-021-00317-4 – ident: e_1_3_3_64_2 doi: 10.1186/1471-2105-13-S16-S9 – ident: e_1_3_3_9_2 doi: 10.1021/ac50048a002 – ident: e_1_3_3_6_2 doi: 10.3389/fbioe.2020.603488 – volume-title: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use year: 1994 ident: e_1_3_3_45_2 – ident: e_1_3_3_33_2 doi: 10.1128/JVI.02759-06 – volume-title: M10 Bioanalytical method validation and study sample analysis guidance for industry year: 2022 ident: e_1_3_3_44_2 – ident: e_1_3_3_43_2 doi: 10.1128/JVI.01371-15 – ident: e_1_3_3_60_2 doi: 10.3389/fbioe.2022.992069 – ident: e_1_3_3_11_2 doi: 10.1016/j.ab.2007.06.043 – ident: e_1_3_3_13_2 doi: 10.1021/pr800535h – ident: e_1_3_3_59_2 doi: 10.1016/j.omtm.2022.12.013 – ident: e_1_3_3_15_2 doi: 10.1074/mcp.O112.020131 – ident: e_1_3_3_62_2 doi: 10.1016/j.ab.2008.03.009 – ident: e_1_3_3_55_2 doi: 10.1371/journal.pone.0131137 – volume-title: HPLC method development and validation for pharmaceutical analysis year: 2004 ident: e_1_3_3_46_2 – ident: e_1_3_3_63_2 doi: 10.1038/nmeth.f.371 – ident: e_1_3_3_19_2 doi: 10.1073/pnas.0832254100 – ident: e_1_3_3_37_2 doi: 10.1021/acs.jproteome.9b00640 – ident: e_1_3_3_26_2 doi: 10.1128/JVI.01400-10 – ident: e_1_3_3_48_2 doi: 10.1128/JVI.73.6.4705-4712.1999 – ident: e_1_3_3_7_2 doi: 10.1038/nmeth.2015 – ident: e_1_3_3_8_2 doi: 10.1021/ac50023a781 – ident: e_1_3_3_58_2 doi: 10.1038/s41467-022-32223-1 – ident: e_1_3_3_35_2 doi: 10.1042/BSR20211930 – ident: e_1_3_3_12_2 doi: 10.1007/s10337-016-3121-1 – ident: e_1_3_3_51_2 doi: 10.1186/1743-422X-6-147 – ident: e_1_3_3_18_2 doi: 10.1007/978-1-59745-255-7 – ident: e_1_3_3_22_2 doi: 10.3389/fviro.2023.1108420 – ident: e_1_3_3_14_2 doi: 10.1074/mcp.M800540-MCP200 – ident: e_1_3_3_39_2 doi: 10.1074/mcp.M700132-MCP200 – ident: e_1_3_3_52_2 doi: 10.1128/JVI.02039-09 – ident: e_1_3_3_47_2 doi: 10.1074/mcp.M110.006593 – ident: e_1_3_3_54_2 doi: 10.1002/jms.4348 – ident: e_1_3_3_5_2 doi: 10.1053/j.gastro.2019.04.003 – ident: e_1_3_3_27_2 doi: 10.1128/JVI.3.4.395-403.1969 – ident: e_1_3_3_49_2 doi: 10.1021/acs.analchem.1c01613 – ident: e_1_3_3_25_2 doi: 10.1073/pnas.73.5.1504 – ident: e_1_3_3_4_2 doi: 10.1080/14760584.2022.2072302 – ident: e_1_3_3_16_2 doi: 10.1016/j.ymeth.2004.08.018 – ident: e_1_3_3_40_2 doi: 10.1002/bmc.5287 – ident: e_1_3_3_32_2 doi: 10.1128/mBio.02063-14 – ident: e_1_3_3_10_2 doi: 10.1021/pr801122b – ident: e_1_3_3_36_2 doi: 10.1016/s0042-6822(03)00421-5 – ident: e_1_3_3_21_2 doi: 10.1016/j.jmb.2023.168096 – ident: e_1_3_3_29_2 doi: 10.1016/j.celrep.2019.12.024 – ident: e_1_3_3_38_2 doi: 10.1038/msb.2008.61 – ident: e_1_3_3_34_2 doi: 10.1038/nsmb.3210 – ident: e_1_3_3_42_2 doi: 10.1128/JVI.67.12.7246-7253.1993 – ident: e_1_3_3_50_2 doi: 10.1073/pnas.221447598 – ident: e_1_3_3_30_2 doi: 10.1128/JVI.3.6.611-618.1969 – ident: e_1_3_3_57_2 doi: 10.1016/j.cell.2015.06.018 – ident: e_1_3_3_24_2 doi: 10.1128/JVI.03276-13 – ident: e_1_3_3_28_2 doi: 10.1073/pnas.0903228106 – ident: e_1_3_3_17_2 doi: 10.1074/mcp.T500029-MCP200 – ident: e_1_3_3_23_2 doi: 10.1158/0008-5472.CAN-13-3306 – ident: e_1_3_3_3_2 doi: 10.3390/v12020223 – ident: e_1_3_3_61_2 doi: 10.1074/mcp.M500230-MCP200 – volume: 88 start-page: 4897 year: 2014 end-page: 4907 ident: B23 article-title: VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications publication-title: J Virol doi: 10.1128/JVI.03276-13 – volume: 67 start-page: 7246 year: 1993 end-page: 7253 ident: B41 article-title: Vesicular stomatitis virus M protein may be inside the ribonucleocapsid coil publication-title: J Virol doi: 10.1128/JVI.67.12.7246-7253.1993 – volume: 21 start-page: 1029 year: 2022 end-page: 1044 ident: B3 article-title: Quantification methods for viruses and virus-like particles applied in biopharmaceutical production processes publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2022.2072302 – volume: 84 start-page: 12609 year: 2010 end-page: 12618 ident: B25 article-title: The matrix protein of vesicular stomatitis virus binds dynamin for efficient viral assembly publication-title: J Virol doi: 10.1128/JVI.01400-10 – volume: 30 start-page: 53 year: 2020 end-page: 60 ident: B28 article-title: Structure of the vesicular stomatitis virus L protein in complex with its phosphoprotein cofactor publication-title: Cell Rep doi: 10.1016/j.celrep.2019.12.024 – volume: 79 start-page: 1003 year: 2016 end-page: 1012 ident: B11 article-title: Comparison of the multiple reaction monitoring and enhanced product ion scan modes for confirmation of stilbenes in bovine urine samples using LC–MS/MS QTRAP system publication-title: Chromatographia doi: 10.1007/s10337-016-3121-1 – volume: 359 start-page: 71 year: 2007 end-page: 86 ident: B17 article-title: Quantitative proteomics by mass spectrometry publication-title: Methods Mol Biol doi: 10.1007/978-1-59745-255-7 – volume: 89 start-page: 11750 year: 2015 end-page: 11760 ident: B42 article-title: Tracking the fate of genetically distinct vesicular stomatitis virus matrix proteins highlights the role for late domains in assembly publication-title: J Virol doi: 10.1128/JVI.01371-15 – volume: 6 year: 2009 ident: B50 article-title: Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms publication-title: Virol J doi: 10.1186/1743-422X-6-147 – volume: 8 start-page: 1860 year: 2009 end-page: 1877 ident: B13 article-title: Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M800540-MCP200 – volume: 51 start-page: 1251 year: 1979 end-page: 1264 ident: B8 article-title: Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation publication-title: Anal Chem doi: 10.1021/ac50048a002 – volume: 28 start-page: 190 year: 2023 end-page: 207 ident: B58 article-title: Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication publication-title: Mol Ther Methods Clin Dev doi: 10.1016/j.omtm.2022.12.013 – volume: 130 start-page: 331 year: 1983 end-page: 341 ident: B55 article-title: Identification of a new protein present in vesicular stomatitis virus-infected Chinese hamster ovary cells as a degradation product of viral M protein publication-title: Virology doi: 10.1016/0042-6822(83)90087-9 – volume: 19 start-page: 1447 year: 2020 end-page: 1458 ident: B36 article-title: Skyline for small molecules: a unifying software package for quantitative metabolomics publication-title: J Proteome Res doi: 10.1021/acs.jproteome.9b00640 – year: 2022 ident: B43 publication-title: M10 Bioanalytical method validation and study sample analysis guidance for industry ;ICH – volume: 6 start-page: 1809 year: 2007 end-page: 1817 ident: B38 article-title: High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M700132-MCP200 – volume: 93 start-page: 12889 year: 2021 end-page: 12898 ident: B48 article-title: Liquid chromatography-multiple reaction monitoring-mass spectrometry assay for quantitative measurement of therapeutic antibody cocktail REGEN-COV concentrations in COVID-19 patient serum publication-title: Anal. Chem doi: 10.1021/acs.analchem.1c01613 – volume: 73 start-page: 1504 year: 1976 end-page: 1508 ident: B24 article-title: Sequential transcription of the genes of vesicular stomatitis virus publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.73.5.1504 – volume: 5 year: 2014 ident: B31 article-title: Arenavirus stable signal peptide is the keystone subunit for glycoprotein complex organization publication-title: mBio doi: 10.1128/mBio.02063-14 – volume: 73 start-page: 4705 year: 1999 end-page: 4712 ident: B47 article-title: Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus publication-title: J Virol doi: 10.1128/JVI.73.6.4705-4712.1999 – volume: 9 start-page: 555 year: 2012 end-page: 566 ident: B6 article-title: Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions publication-title: Nat Methods doi: 10.1038/nmeth.2015 – volume: 54 start-page: 481 year: 2019 end-page: 487 ident: B53 article-title: Influence of the amino acid composition on the Ionization efficiencies of small peptides publication-title: J Mass Spectrom doi: 10.1002/jms.4348 – volume: 10 year: 2015 ident: B54 article-title: Impact of vesicular stomatitis virus M proteins on different cellular functions publication-title: PLoS One doi: 10.1371/journal.pone.0131137 – volume: 5 start-page: 1146 year: 2006 end-page: 1157 ident: B16 article-title: Absolute quantification of multisite phosphorylation by selective reaction monitoring mass spectrometry determination of inhibitory phosphorylation status of cyclin-dependent kinases* S publication-title: Mol Cell Proteomics doi: 10.1074/mcp.T500029-MCP200 – ident: B44 article-title: 1994 . Validation of Analytical procedures: Text and methodology International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – volume: 369 start-page: 18 year: 2007 end-page: 26 ident: B10 article-title: A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme publication-title: Anal Biochem doi: 10.1016/j.ab.2007.06.043 – volume: 6 year: 2021 ident: B1 article-title: Considerations for bioanalytical characterization and batch release of COVID-19 vaccines publication-title: NPJ Vaccines doi: 10.1038/s41541-021-00317-4 – volume: 13 year: 2022 ident: B57 article-title: Visualizing molecular interactions that determine assembly of a bullet-shaped vesicular stomatitis virus particle publication-title: Nat Commun doi: 10.1038/s41467-022-32223-1 – volume: 10 year: 2022 ident: B59 article-title: Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP publication-title: Front Bioeng Biotechnol doi: 10.3389/fbioe.2022.992069 – volume: 8 start-page: 887 year: 2009 end-page: 899 ident: B12 article-title: Comparison of MS2-Only, MSA, and MS2/MS3 methodologies for phosphopeptide identification publication-title: J Proteome Res doi: 10.1021/pr800535h – volume: 84 start-page: 983 year: 2010 end-page: 992 ident: B51 article-title: Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication publication-title: J Virol doi: 10.1128/JVI.02039-09 – volume: 23 start-page: 513 year: 2016 end-page: 521 ident: B33 article-title: Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb.3210 – volume: 3 year: 2023 ident: B21 article-title: Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina publication-title: Front Virol doi: 10.3389/fviro.2023.1108420 – volume: 162 start-page: 314 year: 2015 end-page: 327 ident: B56 article-title: Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy publication-title: Cell doi: 10.1016/j.cell.2015.06.018 – volume: 4 start-page: 222 year: 2008 end-page: 222 ident: B37 article-title: Selected reaction monitoring for quantitative proteomics: a tutorial publication-title: Mol Syst Biol doi: 10.1038/msb.2008.61 – volume: 8 year: 2020 ident: B5 article-title: High-throughput large-scale targeted proteomics assays for quantifying pathway proteins in Pseudomonas putida Kt2440 publication-title: Front Bioeng Biotechnol doi: 10.3389/fbioe.2020.603488 – volume: 16 year: 2004 ident: B45 publication-title: HPLC method development and validation for pharmaceutical analysis ;Vol ;Pharm Technol Eur – volume: 42 year: 2022 ident: B34 article-title: Lassa virus glycoprotein complex review: insights into its unique fusion machinery publication-title: Biosci Rep doi: 10.1042/BSR20211930 – volume: 10 year: 2011 ident: B46 article-title: Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry* publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M110.006593 – volume: 12 year: 2020 ident: B2 article-title: Quality assessment of virus-like particles at single particle level: a comparative study publication-title: Viruses doi: 10.3390/v12020223 – volume: 74 start-page: 3567 year: 2014 end-page: 3578 ident: B22 article-title: Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-3306 – volume: 11 start-page: 1475 year: 2012 end-page: 1488 ident: B14 article-title: Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics publication-title: Mol Cell Proteomics doi: 10.1074/mcp.O112.020131 – start-page: 71 year: 2006 end-page: 86 ident: B19 publication-title: Quantitative proteomics by mass spectrometry ;p ;New Jersey – volume: 35 start-page: 265 year: 2005 end-page: 273 ident: B15 article-title: The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications publication-title: Methods doi: 10.1016/j.ymeth.2004.08.018 – volume: 314 start-page: 168 year: 2003 end-page: 178 ident: B35 article-title: Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions publication-title: Virology doi: 10.1016/s0042-6822(03)00421-5 – volume: 157 start-page: 537 year: 2019 end-page: 551 ident: B4 article-title: Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus–infected cells and liver to identify pathways associated with disease development publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.04.003 – volume: 13 year: 2012 ident: B63 article-title: Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-13-S16-S9 – volume: 5 start-page: 144 year: 2006 end-page: 156 ident: B60 article-title: Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M500230-MCP200 – volume: 106 start-page: 11713 year: 2009 end-page: 11718 ident: B27 article-title: Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor, P publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0903228106 – volume: 10 start-page: i year: 2013 end-page: ii ident: B62 article-title: Trypsin/Lys-C protease mix for enhanced protein mass spectrometry analysis publication-title: Nat Methods doi: 10.1038/nmeth.f.371 – volume: 5 year: 2008 ident: B52 article-title: Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding publication-title: Virol J doi: 10.1186/1743-422X-5-161 – volume: 36 year: 2022 ident: B39 article-title: Establishment and validation of an SIL‐IS LC–MS/MS method for the determination of ibuprofen in human plasma and its pharmacokinetic study publication-title: Biomed Chromatogr doi: 10.1002/bmc.5287 – volume: 98 start-page: 12701 year: 2001 end-page: 12705 ident: B49 article-title: The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.221447598 – volume: 3 start-page: 395 year: 1969 end-page: 403 ident: B26 article-title: Structural proteins of vesicular stomatitis viruses publication-title: J Virol doi: 10.1128/JVI.3.4.395-403.1969 – volume: 50 start-page: 81A year: 1978 end-page: 92A ident: B7 article-title: Direct analysis of mixtures by mass spectrometry publication-title: Anal Chem doi: 10.1021/ac50023a781 – volume: 100 start-page: 6940 year: 2003 end-page: 6945 ident: B18 article-title: Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0832254100 – volume: 54 start-page: 598 year: 1985 end-page: 607 ident: B40 article-title: Mass and molecular composition of vesicular stomatitis virus: a scanning transmission electron microscopy analysis publication-title: J Virol doi: 10.1128/JVI.54.2.598-607.1985 – volume: 81 start-page: 5649 year: 2007 end-page: 5657 ident: B32 article-title: Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains publication-title: J Virol doi: 10.1128/JVI.02759-06 – volume: 8 start-page: 3746 year: 2009 end-page: 3751 ident: B9 article-title: Rapid optimization of MRM-MS instrument parameters by subtle alteration of precursor and product m/z targets publication-title: J Proteome Res doi: 10.1021/pr801122b – volume: 3 start-page: 611 year: 1969 end-page: 618 ident: B29 article-title: Protein composition of the structural components of vesicular stomatitis virus publication-title: J Virol doi: 10.1128/JVI.3.6.611-618.1969 – volume: 377 start-page: 259 year: 2008 end-page: 266 ident: B61 article-title: Sodium-deoxycholate-assisted tryptic digestion and identification of proteolytically resistant proteins publication-title: Anal Biochem doi: 10.1016/j.ab.2008.03.009 – volume: 435 start-page: 168096 year: 2023 ident: B20 article-title: Therapeutic efficacy of a VSV-GP-based human papilloma virus vaccine in a murine cancer model publication-title: J Mol Biol doi: 10.1016/j.jmb.2023.168096 – volume: 25 start-page: 415 year: 2018 end-page: 424 ident: B30 article-title: Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system publication-title: Gene Ther doi: 10.1038/s41434-018-0034-7 |
| SSID | ssj0001105252 |
| Score | 2.3046937 |
| Snippet | The development of oncolytic viral therapy has gained considerable momentum in recent years. Vesicular stomatitis virus glycoprotein (VSV-GP) is a new... The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the characterization of... ABSTRACT The rapidly developing field of oncolytic virus (OV) therapy necessitates the development of new and improved analytical approaches for the... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0365123 |
| SubjectTerms | absolute quantification Genomics and Proteomics GPC tracking oncolytic virus Research Article |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZhIZBLaZs-to-gQqFQUGNLtiQfk5AHIVuWthtyE5JmlAQSb1pnD_33lWRv2C2lvfRqCVueGc_DM_MNIe_BeRHA1gysECxaPMcaqZH5oKL76pxvfOodnnyWJ7Pq9KK-WBn1lWrCenjgnnC7UPPK6lBIp0TFIehGQ6mt96IG4SAjgUabtxJM5b8rZZrPxoc0ZtTBu7lx8cfi9lNU2XXJ0niike1u-Zo9yrD9f_I1fy-ZXLFBR4_Jo8F5pHv9oZ-QDWyfks1-nOTPbTLdc1mSkH5f2L4IKNOdzgNNtbw3NKMyXLcdTV0l9K7DRQxKYyQK9PzrOTue0lQGf0ln07MDNvkyeUZmR4ffDk7YMDGB2apW98yDxMZybLR3ylqtHNgSAQodSoeoZbDKqVCAdZjWAKWOAQgKp4O0CsRzMmrnLb4kNCioQHusSwlVgdCglYUK8QYWXOHUmHxI5DODyHcmRxNcmyWhTSa04WJMPi4pbO56CI2_bd5PPHjYmNCv84UoE2aQCfMvmRiTd0sOmvi1pBSIbXG-6EzUaDx3XugxedFz9OFRKWMrRRXfTK_xeu0s6yvt9VVG5C5z-perV__j9K_JFo-eU64ylG_IKNIH30bP597tZCH_BczVBqY priority: 102 providerName: Directory of Open Access Journals |
| Title | Absolute quantification of viral proteins from pseudotyped VSV-GP using UPLC-MRM |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38916347 https://journals.asm.org/doi/10.1128/spectrum.03651-23 https://www.proquest.com/docview/3072001678 https://pubmed.ncbi.nlm.nih.gov/PMC11302727 https://doaj.org/article/d524a8f06b7342df898d18acc35d3bd4 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbKVkhcEG-WR2UkJCQkl8RObOe4VJQKWFgBW_Vm2Z4xVKLZQroH_j22kywsqhDX2InjbzzjGc_DhDwF50UAWzOwQrC44znWSI3MBxXVV-d841Pu8Py9PFpWb07qkx0ix1yYAcFu33Zn2ZG_4WyuX-Tkwx_rs_0oduuScXGF7Na8qYoJ2Z3Nlh_e_j5dKdP9bHxwY176bpTBcQy-tR_lsv2X6Zp_h0z-sQcd3iDXB-WRznpq3yQ72N4iV_vrJH_eJouZyysJ6fe17YOAMu50FWiK5f1Gc1WG07ajKauEnne4jkZptESBHn86Zq8XNIXBf6HLxbsDNv84v0OWh68-Hxyx4cYEZqtaXTAPEhvLsdHeKWu1cmBLBCh0KB2ilsEqp0IB1mFqA5Q6GiAonA7SKhB3yaRdtXif0KCgAu2xLiVUBUKDVhYqxA9YcIVTU_IswWdGgplsTXBtRqBNBtpwMSXPR4TNeV9C41-dXyYabDqm6tf5QVwLZmAmAzWvrA6FdEpUHIJuNJTaei9qEA6qKXkyUtBEbkkuENviat2ZKNF4zrzQU3Kvp-hmqOSxlaKKM9NbtN76l-2W9vRrrshdZvcvVw_-G5SH5BqP6lEOJZSPyCQ24uOo3ly4vWEt7-XjgV9Q6P6M |
| linkProvider | American Society for Microbiology |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0IJNCF7Q-C4MMBISEpK3xE5s57GbGIW1o4J12ptl584wtKWDrA_8-9lOOiiaEK-xE8f35TvfFyGvwdXCgy0ZWCFYOPEcq6RGVnsV1Ffn6qqOucOTAzmaFR-Py-M-qjLmwnyPfXlP2y3bniU_fmTseBHd9yPU2ykB8efibCuI3jJnXNwk69F3GKh7fTicfdr_fcOSxx5tvHdlXvtukMNhIb5yJqXS_dfpm3-HTf5xDu1tkLu9AkmHHcbvkRvY3Ce3upaSvx6Q6dAlakL6Y2G7QKAEezr3NMbzntJUmeGkaWnMLKHnLS6CYRqsUaBHX47Y-ymNofBf6Ww63mWTz5OHZLb37nB3xPquCcwWpbpgNUisLMdK105Zq5UDmyNApn3uELX0VjnlM7AO4xig1MEIQeG0l1aBeETWmnmDTwj1CgrQNZa5hCJDqNDKTPnwAQsuc2pA3kTwmZ7sW5MsCq7NEtAmAdpwMSBvlxA2510ZjX9N3ok4uJoYK2CnB4EgTM9QBkpeWO0z6ZQoOHhdaci1rWtRgnBQDMirJQZN4JjoBrENzhetCVKNp-wLPSCPO4xeLRW9tlIUYWd6Bdcr_7I60px8S1W58-QC5urpfwPlJbk9OpyMzfjDwf4zcocHdSmFFspNshYm4vOg7ly4Fz1dXwIvvgIJ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgE4iXaXx3fBkJCQnJW2IntvPYDcpg66iATnuz7NyZTdrSQtYH_ntsJx0UTYjX2ImT393Zd7kvQl6Bq4UHWzKwQrBw4jlWSY2s9iqor87VVR1zh8dHcn9afDwpT_qoypgL0yPYbtv2Ijnyo2TPwff9CPVOSkD8sbjYDltvmTMubpL16KwKPL4-HE4_Hfz-w5LHHm28d2Vee2_Yh8M6fOVMSqX7r9M3_w6b_OMcGm2SjV6BpMOO4nfJDWzukVtdS8mf98lk6BI3If2-sF0gUMKezjyN8bznNFVmOGtaGjNL6LzFRTBMgzUK9PjLMXs_oTEU_hudTg732Pjz-AGZjt593dtnfdcEZotSXbIaJFaWY6Vrp6zVyoHNESDTPneIWnqrnPIZWIdxDFDqYISgcNpLq0A8JGvNrMHHhHoFBegay1xCkSFUaGWmfHiABZc5NSCvI3xmSTSTLAquzRJok4A2XAzImyXCZt6V0fjX5N1Ig6uJsQJ2uhD4wfQCZaDkhdU-k06JgoPXlYZc27oWJQgHxYC8XFLQBImJbhDb4GzRmrCr8ZR9oQfkUUfRq6Wi11aKInyZXqH1yrusjjRnp6kqd55cwFxt_TcoL8jtyduROfxwdPCE3OFBW0qRhfIpWQvz8FnQdi7d856tfwESTAGl |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absolute+quantification+of+viral+proteins+from+pseudotyped+VSV-GP+using+UPLC-MRM&rft.jtitle=Microbiology+spectrum&rft.au=Basu%2C+Rajeswari&rft.au=Dambra%2C+Richard&rft.au=Jiang%2C+Di&rft.au=Sch%C3%A4tzlein%2C+Sophia+A&rft.date=2024-08-06&rft.eissn=2165-0497&rft.spage=e0365123&rft_id=info:doi/10.1128%2Fspectrum.03651-23&rft_id=info%3Apmid%2F38916347&rft.externalDocID=38916347 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |